Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasms 3Urinary Bladder Neoplasms 1Recurrence 1Prostatic Hyperplasia 1Neoplasm Metastasis 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Adenocarcinoma of the Prostate 1

Interventions

Sildenafil Citrate 8Tadalafil 2Surveys and Questionnaires 2Alprostadil 2udenafil 1trametinib 1sotorasib 1selpercatinib 1pembrolizumab 1osimertinib 1mirabegron 1methyl 3-mercaptopropionimidate 1lorlatinib 1dabrafenib 1cemiplimab 1brigatinib 1bicalutamide 1alpha-Tocopherol 1alectinib 1Vitamin E 1Tamoxifen 1Surgical Instruments 1Saline Solution 1Restraint, Physical 1Psychiatric Rehabilitation 1Preservation, Biological 1Pentoxifylline 1Pemetrexed 1Paclitaxel 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Erectile Dysfunction × Dutasteride × Clear all
NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

CHU de Quebec-Universite Laval

Phase 2 Completed
60 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡